Serine/threonine protein kinase
From Proteopedia
(Difference between revisions)
| Line 189: | Line 189: | ||
**[[3a7f]], [[3a7g]], [[3a7h]], [[3a7i]], [[3a7j]], [[3ckw]] – hChk24 kinase domain <br /> | **[[3a7f]], [[3a7g]], [[3a7h]], [[3a7i]], [[3a7j]], [[3ckw]] – hChk24 kinase domain <br /> | ||
| - | **[[4w8e]], [[4w8d]], [[4u8z]], [[4qmm]], [[4qmn]], [[4qmo]], [[4qmp]], [[4qmq]], [[4qms]], [[4qmt]], [[4qmu]], [[4qmv]], [[4qmw]], [[4qmx]], [[4qmy]], [[4qmz]], [[4qna]], [[4qo9]] – hChk Mst3 + inhibitor <br /> | + | **[[4w8e]], [[4w8d]], [[4u8z]], [[4qmm]], [[4qmn]], [[4qmo]], [[4qmp]], [[4qmq]], [[4qms]], [[4qmt]], [[4qmu]], [[4qmv]], [[4qmw]], [[4qmx]], [[4qmy]], [[4qmz]], [[4qna]], [[4qo9]], [[4u8z]] – hChk Mst3 + inhibitor <br /> |
**[[3ckx]] – hChk24 kinase domain + staurosporin <br /> | **[[3ckx]] – hChk24 kinase domain + staurosporin <br /> | ||
**[[3zhp]] – hChk24 kinase domain + calcium-binding protein <br /> | **[[3zhp]] – hChk24 kinase domain + calcium-binding protein <br /> | ||
**[[4o27]] – hChk24 kinase domain (mutant) + calcium-binding protein <br /> | **[[4o27]] – hChk24 kinase domain (mutant) + calcium-binding protein <br /> | ||
**[[4qml]] – hChk Mst3 kinase domain + AMPPNP <br /> | **[[4qml]] – hChk Mst3 kinase domain + AMPPNP <br /> | ||
| - | |||
| - | *'''Chk26 (Mst4)''' | ||
| - | |||
| - | **[[3ggf]] – hChk Mst4 + inhibitor <br /> | ||
| - | **[[4geh]], [[3w8i]] - hChk Mst4 dimerization domain + programmed cell death protein 10<br /> | ||
| - | **[[4fza]], [[4fzd]], [[4fzf]] – hChk Mst4 (mutant) + calcium-binding protein <br /> | ||
*'''Chk25''' | *'''Chk25''' | ||
| Line 206: | Line 200: | ||
**[[3w8h]] – hChk25 regulatory domain + programmed cell death protein 10<br /> | **[[3w8h]] – hChk25 regulatory domain + programmed cell death protein 10<br /> | ||
**[[4nzw]] – hChk25 kinase domain (mutant) + calcium-binding protein <br /> | **[[4nzw]] – hChk25 kinase domain (mutant) + calcium-binding protein <br /> | ||
| + | |||
| + | *'''Chk26 (Mst4)''' | ||
| + | |||
| + | **[[3ggf]] – hChk Mst4 + inhibitor <br /> | ||
| + | **[[4geh]], [[3w8i]] - hChk Mst4 dimerization domain + programmed cell death protein 10<br /> | ||
| + | **[[4fza]], [[4fzd]], [[4fzf]] – hChk Mst4 (mutant) + calcium-binding protein <br /> | ||
*'''Chk32''' | *'''Chk32''' | ||
| Line 211: | Line 211: | ||
**[[4fr4]] – hChk32A<br /> | **[[4fr4]] – hChk32A<br /> | ||
| - | *Chk40 | + | *'''Chk38''' |
| + | |||
| + | **[[6bxi]] – hChk38 kinase domain<br /> | ||
| + | |||
| + | *'''Chk39''' or SPAK | ||
| + | |||
| + | **[[5d9h]] – mChk39 residues 63-403 + ATP<br /> | ||
| + | **[[5dbx]] – mChk39 residues 63-403 (mutant) + AMPPNP<br /> | ||
| + | |||
| + | *'''Chk40''' | ||
**[[5l2q]] – hChk40 kinase homology domain<br /> | **[[5l2q]] – hChk40 kinase homology domain<br /> | ||
| - | *'''Rac-α hChk''' | + | *'''Rac-α hChk'''; domains: pleckstrin homology 1-123; kinase 144-480 |
| - | **[[1h10]], [[1unq]], [[2uvm]] – hRac-α hChk pleckstrin homology domain + inositol tetrakisphosphate<br /> | ||
**[[1unp]], [[1unr]] – hRac-α hChk pleckstrin homology domain <br /> | **[[1unp]], [[1unr]] – hRac-α hChk pleckstrin homology domain <br /> | ||
**[[2uzr]], [[2uzs]] – hRac-α hChk pleckstrin homology domain (mutant) <br /> | **[[2uzr]], [[2uzs]] – hRac-α hChk pleckstrin homology domain (mutant) <br /> | ||
| - | **[[ | + | **[[1h10]], [[1unq]], [[2uvm]] – hRac-α hChk pleckstrin homology domain + inositol tetrakisphosphate<br /> |
**[[4gv1]] - hRac-α hChk kinase domain + inhibitor<br /> | **[[4gv1]] - hRac-α hChk kinase domain + inhibitor<br /> | ||
| - | **[[4ekl]], [[5kcv]] - hRac-α hChk (mutant) + inhibitor<br /> | + | **[[3qkm]], [[4ekl]], [[6ccy]] - hRac-α hChk kinase domain (mutant) + inhibitor<br /> |
| - | **[[4ekk]] - hRac-α hChk (mutant) + glycogen synthase kinase-3 peptide + AMPPNP<br /> | + | **[[3o96]], [[4ejn]] - hRac-α hChk pleckstrin homology+kinase domains + inhibitor<br /> |
| - | **[[ | + | **[[5kcv]] - hRac-α hChk pleckstrin homology+kinase domains (mutant) + inhibitor<br /> |
| - | **[[ | + | **[[4ekk]] - hRac-α hChk kinase domain (mutant) + glycogen synthase kinase-3 peptide + AMPPNP<br /> |
| + | **[[6c0i]] - hRac-α hChk kinase domain + peptide + inhibitor<br /> | ||
| + | **[[3ow4]], [[3qkk]], [[3qkl]], [[6buu]] - hRac-α hChk kinase domain (mutant) + peptide + inhibitor<br /> | ||
*'''Rac-β hChk''' | *'''Rac-β hChk''' | ||
Revision as of 16:48, 18 September 2018
| |||||||||||
3D structures of serine/threonine protein kinase
Updated on 18-September-2018
References
- ↑ Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003 May;3(5):421-9. PMID:12781359
- ↑ Ducat D, Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res. 2004 Nov 15;301(1):60-7. PMID:15501446 doi:http://dx.doi.org/10.1016/j.yexcr.2004.08.016
- ↑ Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene. 2005 Jan 10;24(2):287-91. PMID:15640844 doi:http://dx.doi.org/10.1038/sj.onc.1208272
- ↑ Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev. 2009 Jun;28(1-2):51-63. doi: 10.1007/s10555-008-9168-1. PMID:19165420 doi:http://dx.doi.org/10.1007/s10555-008-9168-1
- ↑ Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci. 2007 Aug;64(15):1930-44. PMID:17530463 doi:http://dx.doi.org/10.1007/s00018-007-7045-7
- ↑ Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002 Dec 1;62(23):6997-7000. PMID:12460918
- ↑ Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013 Aug 1;73(15):4840-51. doi: 10.1158/0008-5472.CAN-12-4089. Epub, 2013 Jun 4. PMID:23737487 doi:http://dx.doi.org/10.1158/0008-5472.CAN-12-4089
- ↑ Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012 Apr 13;149(2):274-93. doi: 10.1016/j.cell.2012.03.017. PMID:22500797 doi:http://dx.doi.org/10.1016/j.cell.2012.03.017
- ↑ Ravindran R, Loebbermann J, Nakaya HI, Khan N, Ma H, Gama L, Machiah DK, Lawson B, Hakimpour P, Wang YC, Li S, Sharma P, Kaufman RJ, Martinez J, Pulendran B. The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation. Nature. 2016 Mar 24;531(7595):523-7. doi: 10.1038/nature17186. Epub 2016 Mar 16. PMID:26982722 doi:http://dx.doi.org/10.1038/nature17186
- ↑ Atilla-Gokcumen GE, Di Costanzo L, Meggers E. Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3beta. J Biol Inorg Chem. 2010 Sep 7. PMID:20821241 doi:10.1007/s00775-010-0699-x

